1. Most Discussed
  2. Gainers & Losers
GTG 1.1¢

US Market Good Growth

  1. Stocks78

    2,782 Posts.
    5
    Is Optimism For Genetic Technologies Limited (ADR) (NASDAQ:GENE) Fading?

    Following a week of huge gains, thinly traded nano-cap stock Genetic Technologies Limited (ADR) (NASDAQ:GENE) has tumbled again. The shares of the company shed 22.71% in the last trading session, which followed a further slide of 2.15% during the pre-market hours? The stock values at $2.73 currently. There has been no update or news pertaining to the company that could cause such downfall in the shares.


    Rally Fading


    The company announced last week that six breast cancer diagnosis or treatment centres would start offering BREVAGenplus, a move indicating positive future prospects for the company. The announcement by the company had propelled its shares higher by over 183% on the day. However, the rally in the micro-cap stock appears to be fading. The company had said that at least six new breast cancer treatment centers will begin offering the company’s predictive test to patients. The new centers are expected to launch by March while the company anticipates the number of centers to increase going forward.

    Optimistic about the development, Genetic Technologies Limited (ADR) (NASDAQ:GENE) accredited the development to its revised sales strategy. The company said that it would focus more on large and comprehensive breast care centers as well as imaging points. The idea is to tap into higher potential in these centers, which have long sales cycle though. The company said that it expected lower volatility in test volumes on the backdrop of the shift in its sales strategy.

    Applause For Gene

    An applauding reaction to Genetic Technologies Limited (ADR) (NASDAQ:GENE)’s announcement was normal given the increasing number of breast cancer cases emerging in the United states. It is to noted that every 1 in 8 women is exposed to the threat of invasive breast cancer. At the same time, nearly 85% of the breast cancer patients do not have any family background of breast cancer, which accentuates the significance of companies engaged in serving this field of medicine.

    Technicals
    image.jpg
    2011 was both the best and worst year for Genetic Technologies Limited (ADR) (NASDAQ:GENE) as it experienced an amazing rally to $50 levels from the lows of $5 and subsequently dropped to $15 before the year ended. The bear market is not finished yet with every demand zone turning into strong supply area every month. The channel that contains the downmove for the last few months show the first major resistance at $5 now and despite the latest spike in both price and volume, the resistance may survive for now.

    https://www.usmarketsdaily.com/is-o...chnologies-limited-adr-nasdaqgene-fading-8821

DISCLAIMER:
Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.

Top

Thank you for visiting HotCopper

We have detected that you are running ad blocking software.


HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.